ALS genetic modifiers that increase survival of SOD1 mice and are suitable for therapeutic development.
about
Microglia centered pathogenesis in ALS: insights in cell interconnectivityAutomated longitudinal monitoring of in vivo protein aggregation in neurodegenerative disease C. elegans modelsThe tyrosine kinase receptor Tyro3 enhances lifespan and neuropeptide Y (Npy) neuron survival in the mouse anorexia (anx) mutation.Genetic Modifiers for Neuromuscular DiseasesNeuron-specific antioxidant OXR1 extends survival of a mouse model of amyotrophic lateral sclerosisNOX2 As a Target for Drug Development: Indications, Possible Complications, and Progress.Targeting the full length of the motor end plate regions in the mouse forelimb increases the uptake of fluoro-gold into corresponding spinal cord motor neuronsPhosphorylation of Nox1 regulates association with NoxA1 activation domain.Minimally invasive transplantation of iPSC-derived ALDHhiSSCloVLA4+ neural stem cells effectively improves the phenotype of an amyotrophic lateral sclerosis model.Rare genetic variation in UNC13A may modify survival in amyotrophic lateral sclerosis.MMP-9 in translation: from molecule to brain physiology, pathology, and therapy.New Insights on the Mechanisms of Disease Course Variability in ALS from Mutant SOD1 Mouse Models.Selective mitochondrial Ca2+ uptake deficit in disease endstage vulnerable motoneurons of the SOD1G93A mouse model of amyotrophic lateral sclerosis.Glycoursodeoxycholic acid reduces matrix metalloproteinase-9 and caspase-9 activation in a cellular model of superoxide dismutase-1 neurodegeneration.
P2860
Q27009559-C8435BE0-F636-476B-A917-69FB1BF53790Q27301158-AAE9FF95-4062-43A1-B8DF-F0D3941A7859Q33746241-AA50FC10-919D-45A1-B6BB-1BCEE88BEA82Q35119976-013F01F0-273A-42C8-9403-4E78214685F2Q35529701-047E2D51-EB2A-45A6-948F-13826D556FE6Q35985407-540B7E2E-19BD-460F-A214-AB9754B925A2Q36854770-A5AB5AE2-C31E-458C-8353-206B3ED2E79CQ37261114-B61272EE-B701-4368-9C58-B3BD60F1B92CQ37406411-575A5D8B-922C-42A4-9C80-5DF4CBEEA179Q37445251-47B4C9B4-9300-47D3-9669-F9BE32DB843AQ38622769-DF632607-41CE-4D6C-B3AB-CF0B9017AD86Q38701109-C7ABF291-8A55-4240-B3C5-DDDB20FB6D23Q39468775-0E8EA432-20C1-4CDE-A857-3F4F287F3503Q46891717-3D88A6CF-EFC0-4EA0-AE9B-0FA7709D34D9
P2860
ALS genetic modifiers that increase survival of SOD1 mice and are suitable for therapeutic development.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
ALS genetic modifiers that inc ...... e for therapeutic development.
@en
ALS genetic modifiers that inc ...... e for therapeutic development.
@nl
type
label
ALS genetic modifiers that inc ...... e for therapeutic development.
@en
ALS genetic modifiers that inc ...... e for therapeutic development.
@nl
prefLabel
ALS genetic modifiers that inc ...... e for therapeutic development.
@en
ALS genetic modifiers that inc ...... e for therapeutic development.
@nl
P2093
P1476
ALS genetic modifiers that inc ...... e for therapeutic development.
@en
P2093
Chiara Simone
Giacomo P Comi
Giulietta Riboldi
Marianna Falcone
Monica Nizzardo
P304
P356
10.1016/J.PNEUROBIO.2011.07.009
P577
2011-07-26T00:00:00Z